MX2020001223A - Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. - Google Patents

Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.

Info

Publication number
MX2020001223A
MX2020001223A MX2020001223A MX2020001223A MX2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A
Authority
MX
Mexico
Prior art keywords
tatk
compositions
formulations
cdkl5 fusion
fusion proteins
Prior art date
Application number
MX2020001223A
Other languages
English (en)
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of MX2020001223A publication Critical patent/MX2020001223A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere composiciones y formulaciones que contienen una proteína de fusión TATk-CDKL5. También se describen métodos para producir una proteína de fusión TATk-CDKL5 a partir de vectores que contienen ADNc de TATk-CDKL5 y métodos para transducir células con los vectores que contienen ADNc de TATk-CDKL5 y la proteína de fusión TATk-CDKL5.
MX2020001223A 2014-02-28 2015-02-27 Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. MX2020001223A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
PCT/IB2015/000999 WO2015128746A2 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (1)

Publication Number Publication Date
MX2020001223A true MX2020001223A (es) 2022-05-31

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011167A MX2016011167A (es) 2014-02-28 2015-02-27 Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
MX2020001223A MX2020001223A (es) 2014-02-28 2015-02-27 Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016011167A MX2016011167A (es) 2014-02-28 2015-02-27 Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.

Country Status (32)

Country Link
US (4) US9290746B2 (es)
EP (2) EP3608334B1 (es)
JP (2) JP6629747B2 (es)
KR (1) KR102307276B1 (es)
CN (1) CN106255706A (es)
AU (2) AU2015221860B2 (es)
BR (1) BR112016019868B1 (es)
CA (1) CA2940401C (es)
CL (1) CL2016002142A1 (es)
CR (1) CR20160392A (es)
CY (2) CY1122644T1 (es)
DK (2) DK3110837T3 (es)
DO (1) DOP2016000220A (es)
EA (2) EA038000B1 (es)
ES (2) ES2745335T3 (es)
HR (2) HRP20191511T1 (es)
HU (2) HUE055282T2 (es)
IL (2) IL247481B (es)
LT (2) LT3608334T (es)
MX (2) MX2016011167A (es)
MY (1) MY181566A (es)
NI (1) NI201600127A (es)
PE (1) PE20161406A1 (es)
PH (1) PH12016501689B1 (es)
PL (2) PL3110837T3 (es)
PT (2) PT3110837T (es)
RS (2) RS59344B1 (es)
SG (2) SG10202000537RA (es)
SI (2) SI3110837T1 (es)
SV (1) SV2016005264A (es)
WO (1) WO2015128746A2 (es)
ZA (2) ZA201606655B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2940401C (en) * 2014-02-28 2022-11-29 Alma Mater Studiorum-Universita Di Bologna Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
AU2017290047A1 (en) * 2016-06-28 2019-01-17 Alma Mater Studiorum - Universitá Di Bologna TATĸ-CDKL5 fusion proteins, compositions, formulations, and use thereof
US20200299654A1 (en) * 2017-11-30 2020-09-24 Amicus Therapeutics, Inc. Cdkl5 expression variants and cdkl5 fusion proteins
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
AU2020372988A1 (en) * 2019-10-30 2023-06-01 Amicus Therapeutics, Inc. Recombinant CDKL5 proteins, gene therapy and production methods
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
CA3200192A1 (en) 2020-12-01 2022-06-09 Justin PERCIVAL Compositions and uses thereof for treatment of angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055826A1 (en) * 2010-10-25 2012-05-03 Universite De La Mediterranee (Aix-Marseille Ii) TREATMENT OF MeCP2-ASSOCIATED DISORDERS
CA2940401C (en) * 2014-02-28 2022-11-29 Alma Mater Studiorum-Universita Di Bologna Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Also Published As

Publication number Publication date
EA202190727A3 (ru) 2021-11-30
US10584318B2 (en) 2020-03-10
JP6896050B2 (ja) 2021-06-30
NZ723371A (en) 2023-11-24
NI201600127A (es) 2017-03-13
EP3608334A1 (en) 2020-02-12
CN106255706A (zh) 2016-12-21
WO2015128746A3 (en) 2015-11-26
WO2015128746A2 (en) 2015-09-03
US20150247134A1 (en) 2015-09-03
KR102307276B1 (ko) 2021-09-30
IL275435A (en) 2020-08-31
IL275435B (en) 2021-07-29
BR112016019868B1 (pt) 2023-11-28
RS59344B1 (sr) 2019-10-31
US10907138B2 (en) 2021-02-02
EP3110837A2 (en) 2017-01-04
ZA201606655B (en) 2020-05-27
US9944910B2 (en) 2018-04-17
RS62244B1 (sr) 2021-09-30
ES2745335T3 (es) 2020-02-28
SG10202000537RA (en) 2020-03-30
PL3110837T3 (pl) 2020-04-30
PT3110837T (pt) 2019-09-12
LT3110837T (lt) 2019-10-10
US20200199549A1 (en) 2020-06-25
EP3608334B1 (en) 2021-05-19
DK3110837T3 (da) 2019-09-16
JP2017507655A (ja) 2017-03-23
JP6629747B2 (ja) 2020-01-15
CA2940401C (en) 2022-11-29
SG11201606863YA (en) 2016-09-29
IL247481A0 (en) 2016-11-30
EP3110837B1 (en) 2019-06-12
PE20161406A1 (es) 2017-01-14
US20160194617A1 (en) 2016-07-07
HUE055282T2 (hu) 2021-11-29
AU2015221860B2 (en) 2019-09-12
IL247481B (en) 2020-07-30
AU2015221860A1 (en) 2016-09-08
PT3608334T (pt) 2021-08-25
AU2019219743A1 (en) 2019-09-19
CY1124727T1 (el) 2022-07-22
CY1122644T1 (el) 2021-03-12
DK3608334T3 (da) 2021-08-23
US9290746B2 (en) 2016-03-22
CA2940401A1 (en) 2015-09-03
ES2885245T3 (es) 2021-12-13
AU2019219743B2 (en) 2020-10-29
MX2016011167A (es) 2017-04-06
PL3608334T3 (pl) 2021-11-22
KR20170002372A (ko) 2017-01-06
DOP2016000220A (es) 2016-12-15
EA038000B1 (ru) 2021-06-22
SI3110837T1 (sl) 2019-12-31
EA201691691A1 (ru) 2017-05-31
HRP20191511T1 (hr) 2019-11-29
PH12016501689A1 (en) 2016-10-03
CR20160392A (es) 2017-06-12
HUE045393T2 (hu) 2019-12-30
SV2016005264A (es) 2017-02-15
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
US20180327725A1 (en) 2018-11-15
CL2016002142A1 (es) 2017-09-08
HRP20211324T1 (hr) 2021-11-26
ZA201906304B (en) 2022-03-30
BR112016019868A2 (pt) 2017-10-17
JP2020062022A (ja) 2020-04-23
SI3608334T1 (sl) 2021-11-30
EA202190727A2 (ru) 2021-07-30
PH12016501689B1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
MX2019007020A (es) Anticuerpos il-11.
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2019007021A (es) Anticuerpos il-11ra.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MY191581A (en) Anti-pd-1 antibodies
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MY193650A (en) Extracellular matrix compositions
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2020012893A (es) Formulaciones de proteinas.
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
HK1246215A1 (zh) 去細胞角膜及其製備方法和用途
WO2015143240A3 (en) Compositions and methods comprising 2-(acylamino)imidazoles
EP3503911A4 (en) COMPOSITIONS CONTAINING HYBRID ALBUMIN PROTEIN AND ANALOGUES THEREOF, PROCESSES FOR THE PRODUCTION AND USE OF THE SAME
WO2015184326A8 (en) Conjugates, particles, compositions, and related methods